Checklist for IND Readiness Reviews Before Filing Gene Therapy Applications As the pharmaceutical landscape evolves, gene therapy represents a transformative area of treatment, offering potential cures and innovative solutions to previously incurable diseases. However, before commencing clinical trials, it is imperative that organizations navigate the complex web of regulatory requirements set forth by the U.S. Food and Drug Administration (FDA). This guide serves as a comprehensive checklist for Investigational New Drug (IND) readiness reviews prior to filing gene therapy applications, focusing on CMC (Chemistry, Manufacturing, and Controls), nonclinical, and clinical requirements. Understanding IND Requirements in Gene Therapy Trials The IND…

Governance for Version Control and Updates to Active Gene Therapy INDs Governance for Version Control and Updates to Active Gene Therapy INDs The landscape for gene therapy is complex and evolving, necessitating rigorous adherence to regulatory expectations from the U.S. Food and Drug Administration (FDA). This tutorial provides a detailed guide on governance for version control and updates to active Investigational New Drug (IND) applications specifically for gene therapy products. Our aim is to empower regulatory, Chemistry, Manufacturing, and Controls (CMC), clinical and Quality Assurance (QA) leaders in understanding and executing compliant policies concerning IND requirements in gene therapy trials,…

Templates for CMC, nonclinical and clinical sections in gene therapy INDs Templates for CMC, nonclinical and clinical sections in gene therapy INDs The development of cell and gene therapy products presents unique regulatory challenges, especially when it comes to the preparation and submission of Investigational New Drug (IND) applications. To facilitate this process, this tutorial provides a comprehensive review of the templates and specific requirements for the Chemistry, Manufacturing, and Controls (CMC), nonclinical, and clinical sections of gene therapy IND submissions in compliance with 21 CFR Part 312. Attention will also be given to best practices, common pitfalls, and relevant…

Global Alignment of Gene Therapy IND Requirements with EU and UK Expectations The regulatory landscape for gene therapy is rapidly evolving, making it essential for professionals in the field to understand the various requirements laid out by the US FDA, as well as the expectations from regulatory authorities in the EU and UK. This article provides a comprehensive, step-by-step tutorial on the Investigational New Drug (IND) requirements for gene therapy trials, focusing on Chemistry, Manufacturing, and Controls (CMC), nonclinical, and clinical aspects. By aligning these requirements globally, stakeholders can ensure a streamlined process for bringing innovative gene therapies to market….

Incorporating Patient Advocacy Input into Gene Therapy IND Strategies In recent years, the U.S. Food and Drug Administration (FDA) has intensified its focus on engaging stakeholders, particularly patient advocacy organizations, to ensure that the voices of patients are incorporated into regulatory strategies. This is particularly essential in the context of gene therapy products, where the implications of clinical decisions are profound and personal. This tutorial will provide a comprehensive, step-by-step guide on how to systematically incorporate patient advocacy input into Investigational New Drug (IND) strategies for gene therapy trials, focusing on Chemistry, Manufacturing and Controls (CMC), nonclinical, and clinical requirements….